Anterior Advantage With KINCISE

Sponsor
DePuy Orthopaedics (Industry)
Overall Status
Recruiting
CT.gov ID
NCT04191733
Collaborator
(none)
400
12
2
38
33.3
0.9

Study Details

Study Description

Brief Summary

This is a post-market prospective, 1:1 randomized, multicenter non-inferiority study to compare the femoral broaching time for THA with the Anterior Advantage approach with KINCISE vs. without KINCISE. Follow-up will continue through 24 weeks post-op.

Condition or Disease Intervention/Treatment Phase
  • Device: KINCISE(TM) Surgical Automated System
N/A

Detailed Description

The primary endpoint is femoral broaching time (in minutes), which is collected intraoperatively. The primary objective is to demonstrate that femoral broaching time with KINCISE is non-inferior to femoral broaching time with manual instruments (not using KINCISE) when used in THA with Anterior Advantage.

Note: If non-inferiority is successfully demonstrated, then the study will be deemed to be successful, and a test for superiority of femoral broaching time will be conducted.

If the primary endpoint analysis successfully demonstrates non-inferiority of femoral broaching time, then the following three secondary objectives will be assessed with formal hypotheses, in order, under a gatekeeping strategy:

  • Non-inferiority of skin-to-skin OR time when KINCISE is used vs. when KINCISE is not used.

  • Non-inferiority of the percent of subjects with optimal acetabular cup abduction angle when KINCISE is used vs. when KINCISE is not used.

  • Non-inferiority of the percent of subjects with optimal acetabular cup version angle when KINCISE is used vs. when KINCISE is not used.

In addition, the following secondary endpoints do not have prospectively planned hypotheses; these will be summarized for both treatment groups:

  • Harris Hip Score (HHS) and HHS change from preoperative baseline

  • Forgotten Joint Score (FJS) and FJS change from 6-week postoperative baseline

  • EQ-5D-5L and changes in these assessments from preoperative baseline

  • Pain (Groin, Thigh, and Buttock)

  • Patient Satisfaction

  • Post-op time when functional activities can be accomplished (return to work, self-care, etc.)

  • Radiographic Outcomes (based upon AP Hip, AP Pelvis, and Lateral)

  • Length of hospital stay after index THA

  • Re-hospitalizations during the study (including a specific summary of re-hospitalizations within 90 days)

  • Narcotic drug usage throughout the study (participant reported)

  • Complications (including a specific summary of complications within 90 days post-surgery)

Study Design

Study Type:
Interventional
Anticipated Enrollment :
400 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Intervention Model Description:
1:1 Block Randomization1:1 Block Randomization
Masking:
None (Open Label)
Primary Purpose:
Treatment
Official Title:
Prospective, Randomized, Multi-center Post-Market Study of Anterior Advantage Surgical Approach in Total Hip Arthroplasty With and Without the KINCISEā„¢ Surgical Automated System.
Actual Study Start Date :
Jan 28, 2020
Anticipated Primary Completion Date :
Dec 28, 2022
Anticipated Study Completion Date :
Mar 31, 2023

Arms and Interventions

Arm Intervention/Treatment
Experimental: Anterior Approach with KINCISE

Anterior Approach THA using KINCISE(TM) Surgical Automated System

Device: KINCISE(TM) Surgical Automated System
Uncemented Total Hip Arthroplasty via Anterior Approach with and without the KINCISE(TM) Surgical Automated System

Active Comparator: Anterior Approach without KINCISE

Anterior Approach THA with a mallet (without KINCISE)

Device: KINCISE(TM) Surgical Automated System
Uncemented Total Hip Arthroplasty via Anterior Approach with and without the KINCISE(TM) Surgical Automated System

Outcome Measures

Primary Outcome Measures

  1. Femoral Broach Time [Operative]

    The primary endpoint analysis is to demonstrate that femoral broaching time (in minutes) with KINCISE is non-inferior to femoral broaching time with manual instruments (not using KINCISE) under a non-inferiority margin of 1.25 minutes.

Secondary Outcome Measures

  1. Skin-to-skin Time [Operative]

    A non-inferiority test of skin-to-skin OR time will be conducted with a non-inferiority margin of 3.75 minutes, using a 2-sample t-test

  2. Cup Abduction Angle [6 weeks post-op]

    A non-inferiority test of the percent of subjects with acetabular cup abduction angle within +/- 10 degrees of plan under a NI margin of 10%

  3. Cup Version Angle [6 weeks post-op]

    A non-inferiority test of the percent of subjects with acetabular cup version angle within +/- 10 degrees of plan under a NI margin of 10%

  4. Harris Hip Score [Baseline (pre-op), 6 and 24 weeks]

    Harris Hip Score (HHS) and HHS change from preoperative baseline

  5. Forgotten Joint Score (FJS-12) [6 and 24 weeks]

    Forgotten Joint Score (FJS) and FJS change from 6-week postoperative baseline

  6. Pain (Patient Questionnaire) [Baseline (pre-op), 6 and 24 weeks]

    Pain (Groin, Thigh, and Buttock); determined via patient questionnaire

  7. Patient Satisfaction (Patient Questionnaire) [Baseline (pre-op), 6 and 24 weeks]

    Assessment of expected satisfaction pre-operatively and post-op patient satisfaction at 6 and 24 weeks post-op

  8. Functional Outcomes [Baseline (pre-op), 6 and 24 weeks]

    Post-op time when functional activities can be accomplished (return to work; self-care; etc.)

  9. Length of Stay [Operative/Discharge (Day 0 to day of discharge)]

    Length of hospital stay after index THA

  10. Re-hospitalizations [24 weeks]

    Re-hospitalizations during the study (including a specific summary of re-hospitalizations within 90 days)

  11. Narcotic Drug Use [24 weeks]

    Narcotic drug usage throughout the study. This will be reported by the participant.

  12. Complications [24 weeks]

    Complications (including a specific summary of complications within 90 days post-surgery)

  13. Acetabular Cup Position [6 and 24 weeks]

    Measure (in degrees) of acetabular cup inclination and version

  14. Acetabular Cup Migration [6 and 24 weeks]

    Measure and summary of any reports of acetabular cup migration

  15. Acetabular Cup Radiographic Outcomes [6 and 24 weeks]

    Measure and summary of any reports of acetabular cup radiolucency, osteolysis, and sclerotic lines

  16. Femoral Stem Position [6 and 24 weeks]

    Measure and summary of femoral stem position, tilt and subsidence

  17. Femoral Stem Radiographic Outcomes [6 and 24 weeks]

    Measure and summary of any reported femoral stem radiolucency, osteolysis, sclerotic lines

Eligibility Criteria

Criteria

Ages Eligible for Study:
21 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  1. The patient is undergoing a standard of care primary cementless hip replacement with the Pinnacle cup and a Corail or Actis stem via the Anterior Advantage approach. All devices are to be used according to the approved indications.

  2. Individuals who are able to speak, read, and comprehend the Institutional Review Board approved Informed Consent Document and willing and able to provide informed patient consent for participation in the study and have authorized the transfer of his/her information to DePuy Synthes.

  3. Individuals who are willing and able to complete follow-up visits and questionnaires as specified by the study protocol.

  4. Individuals who are not bedridden per the discretion of the investigator (The intent of "not bedridden" means a permanent situation, not a temporary situation as in a hip fracture or trauma case).

  5. Individuals who are a minimum age of 21 years at the time of consent.

Exclusion Criteria:
  1. Active local or systemic infection.

  2. Loss of musculature, neuromuscular compromise or vascular deficiency in the affected limb rendering the procedure unjustified.

  3. Poor bone quality, such as osteoporosis, where, in the surgeon's opinion, there could be considerable migration of the prosthesis or a significant chance of fracture of the femoral shaft and/or the lack of adequate bone to support the implant(s).

  4. Charcot's or Paget's disease.

  5. The Subject is a woman who is pregnant or lactating.

  6. Subject had a contralateral amputation.

  7. Previous partial hip replacement in affected hip.

  8. Subject has participated in a clinical investigation with an investigational product (drug or device) in the last three months.

  9. Contralateral hip was replaced less than 3 months prior to surgery date, contralateral hip is already enrolled in the study, or simultaneous or staged hip replacement is planned

  10. Subject is currently involved in any personal injury litigation, medical-legal or worker's compensation claims.

  11. Subject was diagnosed and is taking prescription medications to treat a muscular disorder that limits mobility due to severe stiffness and pain such as fibromyalgia or polymyalgia.

  12. Subject has a medical condition with less than 2 years of life expectancy.

  13. Subject, in the opinion of the Investigator, is a drug or alcohol abuser or has a physical or psychological disorder that could affect their ability to complete patient reported questionnaires or be compliant with follow-up requirements.

Contacts and Locations

Locations

Site City State Country Postal Code
1 The Orthopedic Specialty Center of Northern California Roseville California United States 95678
2 Colorado Joint Replacement Denver Colorado United States 80210
3 Capital Region Orthopaedic Group Albany New York United States 12208
4 Hospital for Special Surgery New York New York United States 10021
5 Columbia University Medical Center New York New York United States 10032
6 Carolina Orthopaedic & Sports Medicine Gastonia North Carolina United States 28054
7 Cleveland Clinic Cleveland Ohio United States 44195
8 Southern Joint Replacement Institute Nashville Tennessee United States 37203
9 Texas Institute for Hip and Knee Surgery Austin Texas United States 78751
10 W.B. Carrell Memorial Clinic Dallas Texas United States 75231
11 North Texas Medical Research Institute Dallas Texas United States 75254
12 Jordan-Young Institute Virginia Beach Virginia United States 23462

Sponsors and Collaborators

  • DePuy Orthopaedics

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
DePuy Orthopaedics
ClinicalTrials.gov Identifier:
NCT04191733
Other Study ID Numbers:
  • DSJ_2019_03
First Posted:
Dec 10, 2019
Last Update Posted:
Aug 9, 2022
Last Verified:
Aug 1, 2022
Individual Participant Data (IPD) Sharing Statement:
Yes
Plan to Share IPD:
Yes
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
Yes
Product Manufactured in and Exported from the U.S.:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Aug 9, 2022